Total Credits: 1 including 1 AMA PRA Category 1 Credit(s)™, 1 AOA Category 1-A Credit(s)
** Please note this program was a part of the VOC 2023. You will not want to choose this program if you completed this individual program as part of the VOC 2023. **
• Learners will analyze the epidemiology of hypertension.
• Learners will assess how the social determinants of health can be assessed and used to help treat hypertension.
• Learners will recognize and grasp the history of hypertension guidelines and why changes have been made throughout the years.
• Learners will analyze and apply the hypertension guidelines, which include the diagnosis, evaluation, monitoring, and secondary causes of hypertension.
• Learners will integrate the hypertension guidelines into their practice to provide optimal care for their patients.
• Learners will better treat patients by incorporating updated guidelines and SDOH.
Accreditation Statement: This program is co-sponsored by the Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) and the Osteopathic Physicians and Surgeons of Oregon (OPSO). Both osteopathic associations are accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.
The program has been designated for a maximum of one (1) AOA Category 1-A credit(s) by the co-sponsors who have authorized the Missouri Association of Osteopathic Physicians and Surgeons to report CME and specialty credits to the AOA commensurate with the extent of the physician's participation in this activity.
MAOPS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MAOPS designates this conference for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Planning Disclosure: The Virtual CME Committee consisting of representatives from the Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) and the Osteopathic Physicians and Surgeons of Oregon (OPSO), has no relevant financial relationships with any organization producing, marketing, reselling, distributing health care goods or services consumed by, or used on, patients relative to the content of these presentations.
Osteopathic Grievance Policy: All grievances should be in writing and should specify the nature of the grievance. Initially, all grievances should be directed to MAOPS Executive Director, who will then forward said grievance to the Virtual CME Committee. All grievances will receive an initial response in writing within 30 days of receipt. If the participant does not receive a satisfactory response, they can then submit a complaint in writing to the Council on Continuing Medical Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.
|Handout - Sa4B) Dr. William Elliott - Hypertension Guidelines- Incorporating Social Determinants of Health - OPSO (2.82 MB)||58 Pages||Available after Purchase|
|Handout - Sa4B) Dr. William Elliott #2 - Hypertension Guidelines- Incorporating Social Determinants of Health - OPSO (0.16 MB)||4 Pages||Available after Purchase|
Dr. William Elliott is a Professor of Preventive Medicine, Internal Medicine, and Pharmacology, Chief of the Division of Pharmacology, and Chair of The Department of Biomedical Sciences at the Pacific Northwest University of Health Sciences in Yakima, Washington. After receiving the B.S. (summa cum laude) from the University of Notre Dame, he earned an M.D. and Ph.D. (in Bio-Organic Chemistry) from the University of Chicago in Illinois. He trained in Internal Medicine and Pharmacology at Barnes Hospital and Washington University in St. Louis, Missouri. Dr. Elliott served as a faculty member at the University of Chicago from 1985-92. During the next 17 years at Rush Medical College in Chicago, Illinois, he practiced, taught, and researched cardiovascular clinical pharmacology. His focus was on epidemiologic studies of risk factors (including diagonal earlobe creases), laboratory investigations, federally-funded cooperative clinical trials, and many industry-supported endeavors, serving as principal investigator for about 200 clinical trials of new drugs. Dr. Elliott is board certified in Clinical Pharmacology and Internal Medicine from the American Board of Internal Medicine.
One of the inaugural "Specialists in Clinical Hypertension" and Fellows of the American Society of Hypertension, he contributed on five topics to JNC VI and the "long version" of JNC 7. Some of his recent publications include meta-analyses of clinical trial results, putative risk factors for cardiovascular disease, cost-containment, pharmacoeconomics, and the assessment and enhancement of medication adherence. Dr. Elliott belongs to many professional societies interested in clinical pharmacology and hypertension, including a fellowship in the American Heart Association's High Blood Pressure Council. He has lectured on five continents, participated in the review process for many journals, societies, study sections, and funding agencies, and served as editor or co-editor for many books, monographs, and symposia. Among his honors are 29 awards for teaching excellence.
Dr. William Elliott discloses that he has author and editor relationships with Elsevier and Wolters Kluwer, for which he received royalties. He also discloses that he is on the advisory board of Janssen. All relevant financial relationships have been mitigated.